Observational studyMedicine2021

Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.

Shufang Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.